In short. Basal cell carcinoma subtypes, behaviour and treatment: why it destroys locally, why it almost never spreads, and why complete excision still matters.
Key points
- Morphoeic basal cell carcinoma is the reason surgeons excise beyond what the eye can see.
- Its margins are not visible, its cells trail along collagen far from the palpable edge, and a narrow excision that looks complete on the operating table may leave tumour behind.
- When this subtype is suspected on the nose, eyelid or around the ear, margin-controlled serial excision with examination of the entire peripheral margin is often the safer choice than a standard excision.
Basal cell carcinoma is the most common cancer in fair-skinned people, and for most patients it is also the most forgiving. It arises from basal cells at the bottom of the epidermis, grows slowly over months to years, and destroys tissue by local expansion. It very rarely spreads to distant organs. That combination — common, slow, locally destructive, seldom metastatic — shapes everything about how it is treated.
The subtypes and how they behave
Nodular basal cell carcinoma is the classic form: a pearly, translucent lump with visible small vessels and a rolled edge, sometimes with a central crater. Superficial basal cell carcinoma appears as a red, scaly patch, often on the trunk, and is easily mistaken for eczema. Morphoeic or sclerosing basal cell carcinoma is the deceptive one: it looks like a pale, firm, scar-like plaque with indistinct edges, and it extends further under the surface than it appears to. Pigmented basal cell carcinoma is dark enough to be confused with melanoma. The subtype matters because it predicts how far the true tumour extends, and therefore how wide the excision must be.
Why it almost never spreads
Basal cell carcinoma rarely acquires the ability to survive elsewhere. Metastasis is reported but is genuinely rare, usually in the setting of very large, long-neglected or deeply invasive tumours. The danger is therefore local: a tumour near the eyelid, nose, ear or lip can destroy cartilage, muscle and, if neglected, bone.
The deceptive subtype
Morphoeic basal cell carcinoma is the reason surgeons excise beyond what the eye can see. Its margins are not visible, its cells trail along collagen far from the palpable edge, and a narrow excision that looks complete on the operating table may leave tumour behind. When this subtype is suspected on the nose, eyelid or around the ear, margin-controlled serial excision with examination of the entire peripheral margin is often the safer choice than a standard excision.
Treatment
Standard excision with a measured margin of normal skin, confirmed by pathology, is the mainstay and is appropriate for most tumours. Margin-controlled serial excision is preferred for high-risk sites, aggressive subtypes, recurrent tumours and lesions where conserving tissue matters. Curettage and cautery suits small, superficial, low-risk lesions. Topical or light-based treatment may be considered for superficial tumours only, and never where the depth is in doubt. Radiotherapy is reserved for patients who cannot undergo surgery.
Recurrence and follow-up
Complete excision cures the great majority of basal cell carcinomas, but recurrence still occurs in a small percentage, usually within the first few years and most often after incomplete removal or an aggressive subtype. Recurrences tend to be harder to treat than the original tumour. Because having one basal cell carcinoma predicts another, periodic skin review after treatment is part of the plan, not an optional extra.
Seek review promptly if
- A pearly lump, persistent sore or scar-like plaque bleeds, crusts, or fails to heal over several weeks.
- A previously treated site develops a new lump, a raw area, or thickening along the scar.
- A lesion near the eyelid, nose, ear or lip begins to change, since tissue here is unforgiving.
Frequently asked questions
Why does basal cell carcinoma rarely spread, and what harm does it cause instead?
Metastasis is reported but genuinely rare, usually in the setting of very large, long-neglected or deeply invasive tumours. The danger is local: a tumour near the eyelid, nose, ear or lip can destroy cartilage, muscle and, if neglected, bone.
What makes morphoeic basal cell carcinoma harder to treat?
It looks like a pale, firm, scar-like plaque with indistinct edges, and it extends further under the surface than it appears to. Its cells trail along collagen far from the palpable edge, so a narrow excision that looks complete on the operating table may leave tumour behind.
Is topical treatment suitable for every basal cell carcinoma?
No. Topical or light-based treatment may be considered for superficial tumours only, and never where the depth is in doubt. Standard excision with a measured margin, confirmed by pathology, remains the mainstay for most tumours.
Risks & Limitations
- Incomplete excision, which may require a further operation to achieve clear margins.
- Recurrence of the skin cancer, and the need for surveillance for years afterwards.
- Scars are permanent. They mature and fade but never disappear.
- Problems with a graft or flap, including partial or complete loss, which may need further surgery.
- Numbness, altered sensation or nerve injury around the operated area.
- Melanoma carries a risk of spread that surgery cannot remove, even when the excision is complete.
- Pigment change, contour irregularity, or a scar that widens or thickens.
- Final assessment of the scar is made at 6–12 months, and surveillance continues longer.
When to Seek Care
- A lesion that changes in size, shape, colour or height, or that starts to bleed or itch.
- A new, rapidly growing nodule, or a sore that is not healing.
- A mole that becomes painful or bleeds.
- Swelling in a lymph node region — the neck, armpit or groin.
- A graft or flap that turns dark, cold or black, or a wound that opens or discharges.
- Fever above 38 °C, or spreading redness, warmth or pain around a wound.
References & Further Reading
- American Academy of Dermatology (AAD) — skin cancer diagnosis and treatment guidance
- American Cancer Society (ACS) — skin cancer types, staging and outlook
- Skin Cancer Foundation — prevention and skin self-examination resources
- American Society of Plastic Surgeons (ASPS) — reconstruction after skin cancer excision
- Cochrane Library — systematic reviews in skin cancer treatment and prevention
- Chinese Medical Association — clinical guidance for skin tumours and dermatologic surgery
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.